Back to Trades
Total Value
$500.2K
Net $97.6K sold
Filing Date
Jul 17, 2026
1 transaction
Sales
$97.6K
1 transaction
Trade Summary
On Jul 15, 2026 through Jul 17, 2026, Thomson David, Insider, sold $500.2K of MANNKIND CORP (MNKD) across 1 transaction. The filing covers Common Stock, $0.01 Par Value and reflects net selling of $97.6K. Reported prices ranged from $4.05 to $4.09. Insider transactions are sourced from SEC Form 4 disclosures and should be reviewed alongside company fundamentals and the insider's broader trading history.
Company Information
- Company Name
- MANNKIND CORP
- Ticker Symbol
- MNKD
- CIK
- 0000899460
Insider Information
- Name
- Thomson David
- Role
- Insider
- Location
- DANBURY, CT
Filing Details
- Filing Date
- Jul 17, 2026
- Transaction Date
- Jul 15, 2026
- Accession Number
- 0001193125-26-308131
- Form Type
- 4
- Net Trading Amount
- -$97.6K
Non-Derivative Transactions
| Date | Security | Shares | Price | Type | Value |
|---|---|---|---|---|---|
| Jul 15, 2026 | Common Stock, $0.01 Par Value | 93,790 | — | Exercise | — |
| Jul 15, 2026 | Common Stock, $0.01 Par Value | 51,632 | $4.09 | Tax Withholding | $211.2K |
| Jul 15, 2026 | Common Stock, $0.01 Par Value | 12,662 | $4.09 | Tax Withholding | $51.8K |
| Jul 15, 2026 | Common Stock, $0.01 Par Value | 17,754 | $4.09 | Tax Withholding | $72.6K |
| Jul 15, 2026 | Common Stock, $0.01 Par Value | 16,378 | $4.09 | Tax Withholding | $67.0K |
| Jul 17, 2026 | Common Stock, $0.01 Par Value | 24,109 | $4.05 | Sale | $97.6K |
Derivative Transactions
| Date | Security | Shares | Exercise Price | Type | Value |
|---|---|---|---|---|---|
| Jul 15, 2026 | MNKD derivative | 93,790 | — | Exercise | — |
Want live alerts when Thomson David trades again?
Download Insider Trades to track MNKD, follow insiders, and get mobile alerts when new SEC Form 4 filings are published.
Footnotes
- (F1)A previously reported restricted stock unit award granted on May 25, 2023 vested on July 15, 2026 upon the achievement of performance objectives established by MannKind's compensation committee at the time of the approval of the award. Specifically, (i) the closing price of MannKind's common stock on June 30, 2026 was not less than the closing price on May 25, 2023 and (ii) MannKind's total shareholder return (TSR) over the period from May 23, 2023 to June 30, 2026 was at the 41.5th percentile of the TSR of the Russell 3000 Pharmaceutical & Biotechnology Index over the same period. As a result, the performance objective was achieved at 83% of target, resulting in a total share delivery of 93,790 shares. The acquisition of 113,000 shares pursuant to the restricted stock award was reported in Table II of the Form 4 filed by the Reporting Person on May 26, 2023. The remaining 19,210 shares were forfeited in accordance with the performance vesting criteria.
- (F2)Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3 incident to the vesting of previously reported restricted stock units.
- (F3)Transaction occurred pursuant to Rule 10B5-1 Plan established December 2, 2025.
- (F4)The weighted average sales price of the reported transaction was $4.05 based on a range of prices between $3.98 and $4.13. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.
- (F5)Each restricted stock unit represents a contingent right to receive one share of MNKD common stock.